Reporting of SAEs.xlsâ , Table S3 Reporting of serious adverse events (SAEs) in Clinical study reports (CSRs) and journal articles for Olistat trials. (XLS 65 kb)
The purpose of this study is to determine the maximum tolerated dose(MTD)/Recommended Phase 2 Dose(RP2D) and to evaluate the safety and tolerability of GC1118 when given by intravenous (IV) infusion t
